After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety of infectious diseases with unmet needs.Previously at the top of the French company’s priority list was advancing shots that can defend against Lyme disease and the Zika virus.

在试图为其新型冠状病毒肺炎疫苗创造一个利基市场后，瓦尔内瓦正在努力开发，制造和商业化各种未满足需求的传染病疫苗。此前，这家法国公司的首要任务是推进可以预防莱姆病和寨卡病毒的疫苗接种。

And now, most importantly for Valneva, is the launch of its new vaccine for the chikungunya virus.The shot, which was endorsed by the FDA in November of last year and recommended for use by the CDC in February, is the first vaccine for the virus, which is carried by mosquitos in tropical areas of the world and can cause debilitating muscle pain, with its effects lingering for years in some who have been infected.The arrival of the vaccine comes at a critical period as the world’s tropical regions are growing because of global warming.

现在，对瓦尔内瓦来说最重要的是，它推出了新的基孔肯雅病毒疫苗。该疫苗于去年11月获得美国食品和药物管理局（FDA）的批准，并于2月被美国疾病预防控制中心（CDC）推荐使用，是该病毒的第一种疫苗，该病毒由世界热带地区的蚊子携带，可引起虚弱的肌肉疼痛，其影响在一些感染者中持续多年。由于全球变暖，世界热带地区正在增长，疫苗的到来正值关键时期。

In recent years, the chikungunya virus has been detected in a few of the southernmost areas of the United States; and in Europe, it has turned up in Spain, Italy and France.In launching Ixchiq, Valneva is targeting four types of customers, CEO Thomas Lingelbach said in an interview with Fierce Pharma.

近年来，在美国最南端的一些地区发现了基孔肯雅病毒；在欧洲，它出现在西班牙、意大利和法国。首席执行官托马斯·林格巴赫（ThomasLingelbach）在接受威猛制药（Fierce Pharma）的采访时表示，在推出Ixchiq时，瓦尔内瓦针对四类客户。

The company is marketing Ixchiq to people who live in areas where the virus is prevalent, to travelers who visit those areas, to military units with troops stationed in those areas and to governments stockpiling for outbreaks.“We have four different channels requiring a different set of actions and activities,” Lingelbach said of the marketing push.A single shot of Ixchiq is designed to protect a recipient for five or more years.

该公司正在向生活在病毒流行地区的人们、访问这些地区的旅行者、驻扎在这些地区的军队以及为疫情储备物资的政府推销Ixchiq。“我们有四个不同的渠道，需要不同的行动和活动，”Lingelbach在谈到营销推广时说。Ixchiq的单次注射旨在保护接受者五年或更长时间。

An important plus for the vaccine, according to Lingelbach, is that it provides an identical level of protection and longevity of the immune response.

据Lingelbach介绍，该疫苗的一个重要优点是它提供了相同水平的保护和免疫反应的寿命。